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Abstract: Metabolomics is an emerging new “omics” field involving the systematic analysis 
of the metabolites in a biologic system. These metabolites provide a molecular snapshot of 
cellular activity and are thus important for understanding the functional changes in metabolic 
pathways that drive disease. Recently, metabolomics has been used to study the local and sys-
temic metabolic changes in psoriasis and its cardiometabolic comorbidities. Such studies have 
revealed novel insights into disease pathogenesis and suggest new biochemical signatures that 
may be used as a marker of psoriatic disease. This review will discuss common strategies in 
metabolomics analysis, current findings in the metabolomics of psoriasis, and emerging trends 
in psoriatic metabolomics.
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Introduction
Metabolites are the small molecules that serve as the substrates, intermediates, and 
products of cellular pathways. Collectively, the full spectrum of metabolites in a 
biologic system forms the metabolome, which represents the ultimate culmination of 
gene expression, epigenetics, protein activity, and environmental influences. As such, 
metabolites are a direct, functional reflection of the biochemical processes occurring in 
a particular phenotype. The study of metabolites has long been integral to our under-
standing of human health and disease. The importance of metabolites in medicine was 
first noted by Chinese and Hindu practitioners in the 15th century BC who observed 
that the presence of a sweet compound in urine was associated with the disease now 
known as diabetes. Modern methods of metabolite analysis were pioneered thousands of 
years later in 1971 by Linus Pauling, who used gas chromatography (GC) to analyze the 
composition of breath and urine vapor.1 Despite the history of metabolites in medicine, 
the term “metabolomics” was not formally coined until 1998, when researchers led by 
Oliver et al2 and Tweeddale et al3 separately described the emergence of a new “omics” 
field dedicated to the systematic identification and quantification of the metabolome.
Since then, the role of modern metabolomics in medical research has continued to 
evolve and the metabolome has been increasingly recognized as an essential aspect of 
our understanding of human disease. The profound relationship between health and 
the metabolome is driven by the ability of small shifts in biochemical pathways to 
produce dramatic changes in cellular metabolites. In disorders with clear metabolic 
causes, such as diabetes and heart disease, metabolomics has provided key insights 
into disease pathogenesis.4–6 Yet, even when metabolic derangements do not overtly 
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drive the disease process, the effects of disease can still pro-
voke insightful alterations in the metabolome. For instance, 
inflammatory conditions,7–9 neurodegenerative disease,10 
infections,11,12 and cancer13–15 can all fundamentally change 
cellular metabolism, allowing for the identification of novel 
biomarkers that aid in the prediction, diagnosis, and under-
standing of disease. More recently, metabolomics has been 
applied to dermatology, where it has been used to identify 
characteristic biomarker profiles in metastatic melanoma,16,17 
basal cell carcinoma,18 acute intermittent porphyria,19 and 
atopic dermatitis.20
However, one of the most promising areas of skin 
research has been the application of metabolomics to the 
study of psoriatic disease. Several features of psoriasis sug-
gest that it has metabolic underpinnings important to disease 
pathogenesis, outcomes, and treatment. Most interestingly, 
psoriasis is strongly associated with various cardiometabolic 
comorbidities including atherosclerosis, diabetes, and obe-
sity. Metabolomic studies of these psoriatic comorbities have 
revealed heightened activity of inflammatory pathways21,22 
and a previously unappreciated pathogenic role of metabo-
lites derived from the gut microbiome.6,23,24 Metabolomics 
is, therefore, an ideal approach for investigating the link 
between psoriasis, cardiometabolic comorbidities, and the 
microbiome. Furthermore, unlike genomics and proteomics, 
metabolomics can capture the downstream effects of envi-
ronmental factors, such as diet on psoriasis. This review will 
provide an overview of common analytic strategies used 
in metabolomics, summarize the findings of metabolomic 
studies in psoriasis, and discuss emerging trends in psoriasis 
metabolomics.
Materials and methods
We conducted a systematic review of the literature in PubMed 
and Embase using the Medical Subject Headings terms pro-
vided in Table S1. References from the assembled articles 
were also reviewed. We included only published articles 
from peer-reviewed journals. This search strategy yielded 
126 PubMed and 141 Embase abstracts, which were then 
evaluated by the study team members based on predetermined 
exclusion and inclusion criteria: 1) study involved subjects 
with either psoriasis or psoriatic arthritis and 2) study quanti-
fied endogenous metabolites in human subjects. We excluded 
case reports, in vitro or ex vivo experiments, methodology 
papers, redundant studies, and pharmacokinetic or toxicity 
studies that looked exclusively at the metabolism of specific 
drug or xenobiotic substance. Thirty-eight abstracts were 
selected for review, full-text articles could not be found for 
2 potentially qualifying abstracts, and 16 articles met all 
criteria (Tables 3–5).
Approaches and techniques
Studies of the metabolome can be broadly divided into tar-
geted and untargeted approaches. Targeted metabolomics 
involves the analysis of a prespecified set of metabolites, 
often related to a particular pathway or network of pathways 
of interest. Metabolomic studies can also be untargeted, that 
is, they aim to generate a global picture of metabolic activity 
without focusing on particular metabolites that have been 
defined a priori. One type of approach in untargeted metabo-
lomics is metabolic fingerprinting, which uses a pattern of 
metabolite composition to categorize or identify samples. 
Another untargeted approach is metabolite profiling, which 
refers to the simultaneous measurement of as many metabo-
lites as possible to produce a comprehensive “snapshot” of 
metabolic activity in a biologic system. The data generated by 
untargeted metabolomics are very complex and high volume, 
typically requiring processing with specialized bioinformat-
ics software, such as various forms (X) of chromatography 
mass spectrometry25 and comparison to metabolite databases, 
such as METLIN26 and the Human Metabolome Database.27 
To interpret the processed data in a meaningful way, it must 
then be mapped onto metabolic pathway databases, such as the 
Kyoto Encyclopedia of Genes and Genomes.28 This requires 
sophisticated statistical tools, such as MetaboAnalyst29 and 
MetaMapR,30 to perform pathway and network analyses.
Sample analysis involves the separation of the mixture 
into its biochemical constituents followed by the identifica-
tion and quantification of each component. The most com-
monly used instruments for identification and quantification 
in the study of metabolomics are mass spectrometry (MS) 
and nuclear magnetic resonance (NMR) spectroscopy. Each 
analytical platform has distinct advantages and limitations 
(Table 1). MS ionizes analytes and separates the ions based 
on mass to charge ratio. Although samples can be directly 
injected into a mass spectrometer, MS-based analysis is usu-
ally coupled to a variety of analyte separation techniques, 
which can influence the accuracy and sensitivity of MS-based 
methods (Table 2). These separation methods include GC, 
capillary electrophoresis (CE), and liquid chromatography 
(LC) and its variations, such as high performance liquid 
chromatography (HPLC) and ultra-high performance liquid 
chromatography (UPLC).
Although ideal for volatile and thermally stable com-
pounds, GC requires that the nonvolatile constituents of 
a sample be chemically derivatized to a volatile form for 
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injection into the gas phase.31 Components of the sample 
mixture are then separated based on volatility and size.32 
Derivatization is a significant drawback to the GC separation 
method because it can render sample preparation exces-
sively complex and expensive and introduce experimental 
artifacts (Table 2).31 Because analytes must be volatile, GC 
is not effective for separating large, highly polar, or charged 
compounds and cannot be used on solid samples.33 Other 
limitations of GC–MS include its interbatch variability and 
the time-consuming nature of its sample analysis (20–40 min-
utes per sample).31 Despite its drawbacks, of all the analytic 
methods discussed, GC–MS is the most mature technology 
with established fragmentation libraries for the identification 
of separated sample constituents.
In contrast to GC, LC-based methods perform the 
separation process in the liquid phase and do not require 
derivatization for biologic fluid samples. LC offers a far 
broader range of metabolite coverage than GC, encompassing 
both polar and nonpolar compounds.32 Unlike GC, LC can 
process solid samples in addition to liquid samples. Modern 
LC-based techniques, such as HPLC and UPLC, can detect 
analytes present in concentrations <5 parts per billion.32 
However, LC-based approaches are hampered by the lack 
of MS fragmentation libraries against which analytes can 
be compared and identified.31 Furthermore, GC, LC, and its 
variations are time-consuming, requiring ~15–40 minutes per 
sample.31 LC–MS also has limited quantification capabilities 
compared to NMR.31
A third option is CE, which separates sample components 
by charge and size. CE can thus only be used to separate 
charged and polar metabolites. However, compared to other 
separation techniques, CE is faster, requiring <20 minutes 
per sample and a significantly smaller sample volume 
(1–20 nL).32 CE also offers higher resolution separation 
(plate numbers on the order of 100,000–1,000,000)34,35 and 
can analyze a wider range of metabolites than GC.
In general, MS-based approaches offer higher sensitiv-
ity compared to NMR. Modern MS platforms can detect 
metabolite on the order of picomole to femtomole concentra-
tions.33 MS can also analyze a broader range of metabolites 
simultaneously, allowing for high throughput analyses of the 
metabolome. These advantages make MS-based methods 
more ideal for untargeted metabolomic analyses. However, 
MS-based analyses generate data that are less reproducible 
than NMR results and consume the sample, preventing repeat 
testing. Additionally, most MS techniques offer less detailed 
structural information than NMR, rendering novel metabolite 
identification difficult.
Unlike MS, NMR simultaneously separates, identifies, 
and quantifies sample components based on characteristic 
resonance patterns generated by individual constituents. 
Consequently, NMR does not require prior sample  separation 
Table 1 Comparison of NMR and MS based platforms for metabolite analysis
Sample NMR MS
Recovery Preservation of sample Sample destroyed
Separation Not needed-simultaneously separates and identifies Usually needs to be coupled to separation technique
Derivatization Not needed Yes, if separating by GC
Volume Large (0.1–0.5 mL) Small-Moderate (10–100 µL)
Sensitivity Lower (LOD 0.5 µM) Higher (LOD up to 0.5 nM with LC–MS)
Selectivity Mostly nonselective analysis Selective and nonselective analysis
Identification of unknowns More structural information, better identification 
of unknowns
Difficult to identify new metabolites
Detection range 40–200 metabolites simultaneously 500+ metabolites simultaneously
Analysis time Fast (2–3 minutes/sample) Slow (15–40 minutes/sample)
In vivo Can be used in vivo No, requires sample extraction
Reproducibility High Moderate
Note: Data obtained from various review studies.31,33,36
Abbreviations: GC, gas chromatography; LC, liquid chromatography; LOD, limit of detection; MS, mass spectrometry; NMR, nuclear magnetic resonance.
Table 2 Comparison of separation methods compatible with mass spectrometry
Sample Gas chromatography Capillary electrophoresis Liquid chromatography
Derivatization Yes for nonvolatiles No No
Min volume requirement Moderate (1 µL) Small (1–20 nL) Moderate (15 µL)
Type No solids, only volatile compounds Liquid only No gas, solids must be solubilized
Analyte range Nonpolar and slightly polar Charged and polar Polar and nonpolar
Data interpretation Established libraries for comparison Newer technology, many unknowns Newer technology, many unknowns
Note: Data obtained from various review studies.31–35
Abbreviation: min, minimum.
Psoriasis: Targets and Therapy 2017:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4
Yan et al
or derivatization. In general, NMR requires larger sample 
volumes (0.1–0.5 mL) is a less sensitive technique than MS 
and has a higher limit of detection (5 µM).36 As a result, NMR 
may miss low abundance metabolites. Another disadvantage 
of NMR is that it can only measure ~40–200 compounds 
simultaneously.36 This is considerably less than LC–MS, 
which can analyze over 500 species at a time.36 However, 
NMR can analyze solid and liquid samples and has the 
most unbiased coverage of metabolites, although it cannot 
detect or identify salts, inorganic ions, or nonprotonated 
compounds.31 A unique advantage of NMR is that it provides 
more structural information, facilitating the identification of 
new metabolites. Although NMR is more expensive, the data 
are more reproducible with faster sample processing times 
(2–3 minutes).31 In addition, NMR is nondestructive and can 
be done in vivo or in vitro, allowing for noninvasive analysis 
of living biologic systems.36
As new technological innovations arise, the analytic 
capabilities of NMR and MS-based methods have continued 
to expand and improve. Recently, the development of metabo-
lite imaging has dramatically expanded the applications of 
metabolomics. For example, functional magnetic resonance 
imaging and magnetic resonance spectroscopic imaging use 
NMR-based technology to map metabolites in vivo, allowing 
for imaging of sensitive tissues, such as the neonatal brain.37 
Similarly, desorption electrospray ionization has allowed 
for rapid, intraoperative mapping of oncometabolites to 
guide neurosurgical excisions of patient tumors.38 Molecular 
cartography has also used MS-based approaches to provide 
three dimension (3D) spatial localization of metabolite dis-
tributions on the surface of human skin.39 Other technologic 
developments have enhanced the ability of MS and NMR 
to characterize the structure of metabolites. The use of tra-
ditional proton NMR (1H NMR) in metabolomics can now 
be supplemented with carbon 13 (13C NMR),40 Phosphorus 
31 (31P NMR),41 and 2D NMR.40 Likewise, the application 
of tandem mass spectrometry (MS-MS) provides structural 
information in MS-based analyses.42 These innovations can 
facilitate the identification of unknown metabolites, which 
may serve as novel biomarkers of disease.
Metabolomics in psoriasis and psoriatic 
arthritis
Skin
Differences in metabolites within psoriatic skin lesions 
were identified in several of the studies comparing psoriatic 
lesions to symptom-free psoriatic and/or healthy control 
skin (Table 3). Among these metabolites, a few appear to 
be associated with supporting hyperproliferative or hyper-
metabolic states: glutamic acid, choline, valine, glucose, 
and myo-inositol. This parallels cancer metabolic profiles as 
both diseases are characterized by high cellular proliferation 
rates.43,44 Using NMR and MS techniques, two studies found 
an increase in glutamic acid and glutamic acid:serine ratio 
in psoriatic lesions compared to symptom-free psoriatic skin 
and healthy controls.45,46 This increase in glutamic acid may 
be secondary to an increased demand for glutamine during 
cellular hyperproliferation, rapid protein synthesis, and 
cytokine production-conditions that are commonly involved 
in the pathogenesis of psoriasis.47,48 Similarly, choline is a 
building block needed for cell growth and division and was 
found to be elevated in psoriatic lesional skin compared to 
symptom-free psoriatic skin and healthy controls in two 
studies using NMR and MS analysis.45,49 Moreover, both 
glutamic acid and choline were found to have a positive cor-
relation with psoriasis severity based on the plaque severity 
scale, likely due to the increasing cellular proliferation and 
inflammation.45 Alternatively, decreased levels of glucose, 
myo-inositol, and valine-leucine/isoleucine ratios were found 
in psoriatic lesions compared to nonlesional psoriatic skin, 
which may be due to accelerated turnover of these metabolites 
in rapidly proliferating cells. Interestingly, a study measuring 
metabolites following use of glucocorticoid therapy observed 
changes in choline, glutamic acid, and glucose levels compa-
rable to uninvolved psoriatic skin.49 This reduction in these 
metabolites needed for production highlights the antiprolif-
erative effects of steroids. In addition, the anti-inflammatory 
effects of steroids are noted, as increased levels of choline in 
inflammatory processes have been observed.44
Several metabolites that are altered in psoriatic lesions 
are believed to be due to changes in the metabolic pathway 
secondary to inflammation. Phenylalanine was increased in 
psoriatic lesions compared to symptom-free psoriasis skin 
and healthy controls, but levels were not correlated with 
disease severity.45 Phenylalanine metabolism is interrupted 
by immune activity and, therefore, the metabolite accumu-
lates.50 An increase in taurine and taurine:alanine ratio was 
associated with psoriatic lesions.46,49 Taurine is an abundant 
amino acid in leukocytes and is found in high concentrations 
in inflammatory lesions and tissues exposed to oxidative 
stress.51,52 A decrease in urocanic acid was observed in psori-
atic lesions compared to uninvolved psoriatic skin and healthy 
control.45 Urocanic acid, which is predominantly found in the 
stratum corneum, has been implicated in  immunomodulatory 
effects following ultraviolet light conversion to cis-urocanic 
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Table 3 Metabolomics studies of psoriasis using skin samples
Studies Study objectives Subjects Techniques Key results Implications
Sitter et al49 Explore the metabolic 
pattern of uninvolved 
skin, psoriatic lesional 
skin and corticosteroid 
treated psoriatic skin
10 plaque Ps 
patients each 
provided 3 
skin samples: 
1) Ps lesion, 
2) uninvolved 
skin, 3) Ps 
lesion treated 
with clobetasol 
ointment
1H NMR Ps lesion versus uninvolved: Increased 
choline and taurine, decreased myo-
inositol, and glucose in lesion
In Ps lesion treated versus untreated: 
Glycerophophocholine higher in treated 
skin
Improvement versus no improvement 
after treatment: Patients who improved 
had higher glucose, myo-inositol, GPC 
and glycine, and lower choline
Metabolite changes similar 
to findings in cancer 
patients and may reflect 
hyperproliferation
Metabolites in skin may be 
used to monitor or predict 
treatment response to 
topical steroids
Dutkiewicz 
et al45
Determine differences 
in skin metabolites in 
Ps skin and how these 
changes differ with 
severity of plaques using 
the PSS
100 Ps patients 
(2 samples-
lesional and 
uninvolved)
100 healthy 
volunteers 
matched 
for race, 
age, gender
MS Lesional Ps versus controls: Higher 
choline, glutamic acid, phenylalanine and 
lower lactic acid, urocanic acid, citrulline 
in lesional Ps
Lesional versus nonlesional Ps: Higher 
choline, glutamic acid, phenylalanine, and 
lower lactic acid, urocanic acid, citrulline 
in lesional Ps
Correlated with PSS: Choline, glutamic 
acid positively correlated with severity
Urocanic acid, citrulline negatively 
correlated
Metabolic changes may 
reflect hyperproliferation, 
reduced immunomodulation, 
and impairment of 
phenylalanine metabolism by 
inflammation
Kim et al46 Determine whether 
1H NMR is sufficiently 
sensitive to discern 
differences between 
normal and diseased 
skin
6 Ps patients 
(2 samples-
Ps lesion and 
uninvolved skin)
6 site matched 
skin from 
healthy controls
1H NMR, 
confirmed with 
GC–MS
Glu:Ser, creatine:Gly, and taurine:Ala 
were threefold greater in psoriatic 
lesions compared with symptom free or 
normal skin
Val:Leu/Ile was one-half the normal skin
Similar metabolite changes 
are seen in melanoma and 
may reflect hypermetabolic 
or hyperproliferative state
Uninvolved areas of psoriasis 
patients shared spectral 
patterns in both psoriatic 
plaque areas and healthy 
control skin
Hammarström 
et al62
Compare levels of free 
arachidonic acid, PGE2, 
PGF2, and HETE in 
uninvolved and involved 
epidermis
Uninvolved and 
involved lesions 
of psoriasis 
patients
MS with-
deuterium-
labeled carriers 
and multiple 
ion analysis
Involved epidermis had greater 
arachidonic acid, 12 HETE, PGE2, and 
PGF2a compared to uninvolved skin
The arachidonic acid and 
hydroxyeicosatetraenoic acid levels 
in involved epidermis were strongly 
correlated
The increased levels 
of arachidonic acid 
and 12-HETE in 
involved epidermis 
may have diagnostic 
and pathophysiological 
importance
Brain et al65 Determine whether 
there are differences 
in arachidonic acid 
metabolites between 
untreated lesional 
psoriasis versus 
uninvolved skin
11 patients 
with untreated 
chronic plaque 
Ps (2 samples: 
lesional and 
uninvolved skin)
HPLC Lesional skin had higher LTB4 and also 
contained a biologically active mono-
HETE
Arachidonic pathway 
metabolites leukotriene 
B4 and 12-HETE may play 
role in the pathogenesis of 
the neutrophilic infiltrate in 
psoriasis
Barr et al63 To determine whether 
quantitative analysis 
of several arachidonic 
acid metabolites 
within exudate 
collections of abraded 
skin differs between 
involved psoriasis skin, 
uninvolved psoriasis skin 
and healthy control skin
5 patients 
with chronic 
plaque psoriasis 
(4 males, 1 
female) and 
7 healthy 
controls 
(6 males and 
1 female)
GC–MS Involved Ps versus normal: Increased 
arachidonic acid and 12-HETE in 
involved Ps
Involved versus uninvolved Ps: Increased 
arachidonic acid, 12-HETE in involved Ps
No significant differences between 
healthy normal control and uninvolved 
skin
No significant differences in PGE2
Supports a role of 
lipoxygenase pathway 
products in the pathogenesis 
of psoriasis
Abbreviations: GC, gas chromatography; GPC, glycerophosphorylcholine; HETE, hydroxyeicosatetraenoic acid; 1H NMR, proton nuclear magnetic resonance; HPLC, high 
performance liquid chromatography; LTB4, leukotriene B4; MS, mass spectroscopy; PGE2, prostaglandin E2; PGF2, prostaglandin F2; Ps, psoriasis; PSS, plaque severity scale.
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acid, a natural killer cell activity suppressor.53 Urocanic acid 
has been shown to be negatively correlated with disease 
severity,45 possibly indicating a deficit of local immunosup-
pression by cis-urocanic acid. Other metabolite disturbances 
are likely due to disruption of normal epidermal structures 
and function. For example, a reduction in lactic acid is 
observed in psoriatic lesions compared to nonlesional pso-
riatic skin and healthy controls, which is most likely a result 
of altered metabolism in sweat glands and keratinocytes or 
an obstructed sweat duct.45,54 Citrulline was also found to be 
decreased in psoriatic skin and is generally found attached 
to proteins, which have been found to be reduced in the 
hyperproliferative epidermis and may explain the positive 
correlation with disease severity.45,55
While skin metabolomics have provided biochemical 
evidence of high cell turnover and immune dysregulation 
in psoriasis, they also offer possible mechanisms for kerati-
nocyte hyperproliferation. Abeyakirthi et al56 used HPLC to 
analyze tape strip samples from healthy controls and patients 
with psoriasis. Their study demonstrated increased levels 
of epidermal ornithine and decreased levels of arginine in 
psoriatic lesions. These perturbations suggest overexpres-
sion of arginase 1, an enzyme that competes with induc-
ible nitric oxide synthase (iNOS) for the shared substrate 
arginine. iNOS is responsible for producing high levels of 
NO, which is released from keratinocytes and inhibits cell 
proliferation, whereas promoting differentiation in vivo.57 
Increased use of arginine by arginase 1, reduces its avail-
ability for iNOS, leading to low NO levels, which promotes 
epidermal hyperproliferation in psoriasis.58 Abeyakirthi et al 
found that treatment with an aqueous NO donor gel reduced 
psoriatic plaque severity by 65% compared to a control gel 
in psoriasis patients.56
Outside of the NOS pathway, arachidonic acid metabo-
lites have been of interest as potential contributors to the 
pathogenesis of psoriasis and promising therapeutic targets. 
Arachidonic acid is a polyunsaturated omega-6 fatty acid 
(PUFA) that can be oxidized to a variety of eicosanoids by 
cyclooxygenase21, lipoxygenase22 (LOX), and cytochrome 
P450 enzymes.59 In particular, the LOX pathways produce 
hydroxyeicosatetraenoic acids (HETEs) and leukotriene 
B4 (LTB4), a leukocyte chemoattractant, that is, thought 
to induce keratinocyte activation and neutrophil-mediated 
inflammation in psoriasis.60,61 Several skin-based metabolo-
mics studies have found higher concentrations of arachidonic 
acid,62,63 HETEs,62,63 and LTB464,65 in lesional psoriatic skin, 
suggesting that a shift toward LOX-mediated leukotriene 
production in lesional skin may play a pathogenic role in 
psoriasis. Indeed, the consumption of fish oil or omega-3 
PUFAs may modulate eiconsanoid production and has been 
found to moderately reduce psoriasis symptoms.66
In contrast to the systemic perspective offered by blood 
and urine samples, skin tissue offers the closest look at the 
disease process and the local changes caused by psoriasis. 
Although skin-based metabolomics are the most invasive 
approach, direct sampling of psoriatic lesions allows for the 
correlation of metabolomic data with lesion morphology 
and gene expression data from local inflammatory cells and 
keratinocytes. Skin-based metabolomics, therefore, has the 
greatest potential to elucidate the immune mechanisms that 
drive disease pathogenesis and identify novel therapeutic 
targets. Other applications of skin metabolomics in psoriasis 
include investigating the role of the skin microbiome in local 
immune modulation. More recent technologic innovations 
have enabled the possibility of combining skin metabolomics 
with in vivo NMR and metabolomic imaging to correlate 
metabolite changes with disease activity and tissue archi-
tecture. This approach has already been applied to prostate 
cancer, where it has demonstrated promise in visualizing 
biochemical changes during disease progression and evaluat-
ing cancer aggressiveness.67
Blood
The psoriatic metabolome has not only been studied at the 
level of the skin, but plasma sampling and chromatographic 
techniques have allowed for further exploration of systemic 
perturbations of metabolic processes (Table 4). Blood ratios 
and relative concentrations of key metabolites including 
amino acids, lipids, and fatty-acid derivatives have been 
assessed for their role in the pathogenesis, prognosis, and 
treatment of psoriasis and other autoimmune conditions.
Protein metabolites are often the final products of 
complex metabolic pathways and therefore are the most 
closely correlated with phenotypic manifestations of 
disease. Therefore, understanding the amino acid profiles 
of psoriasis patients can better inform the disease pro-
cess. Understanding the pathogenesis of psoriasis at the 
molecular level has been an ongoing effort in the field of 
psoriasis research. For example, Armstrong et al analyzed 
metabolite differences in psoriasis, psoriatic arthritis, and 
healthy control sera to elucidate the pathogenic processes, 
such as keratinocyte hyperproliferation and immune 
overactivation that underlie psoriasis.47 Armstrong’s study 
found that psoriasis patients exhibited lower overall levels 
of glutamine and asparagine compared to healthy con-
trols. The authors suggested that glutamine, which plays 
Psoriasis: Targets and Therapy 2017:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7
The metabolomics of psoriatic disease
Table 4 Metabolomics studies of psoriasis using blood samples
Studies Study objectives Subjects Techniques Results Implications
Armstrong 
et al47
Differences in metabolite 
profiles among psoriasis 
patients with and without 
psoriatic arthritis and 
healthy controls
10 Ps only
10 Ps and PsA
10 healthy controls
GC–MS Ps versus control: Ps had 
higher alpha ketoglutaric 
acid, lower asparagine, lower 
glutamine
Ps and PsA versus control: Ps 
and PsA had higher glucuronic 
acid
PsA versus Ps: PsA had lower 
alpha ketoglutaric acid, higher 
lignoceric acid
Metabolite changes may 
reflect hyperproliferation, 
hyperfunctioning of immune 
cells, and increased oxidative 
stress
High glucuronic acid may be 
due to joint involvement in PsA
Elevated lignoceric acid in 
both Pso and Psa may reflect 
systemic inflammation and 
metabolic syndrome
Kamleh 
et al69
To determine the plasma 
metabolite differences 
in mild and severe 
psoriasis compared to 
healthy controls and the 
effect of the anti-TNFa 
drug etanercept on the 
metabolite profiles of 
severe psoriasis patients
Pretreatment: 32 with 
mild Ps, 32 with severe 
Ps, 32 healthy control 
Posttreatment: 16 severe 
patients with 12 weeks 
Enbrel treatment
LC–HRMS Anti-TNFa treatment 
normalized metabolite changes
Perturbed pathways associated 
with psoriasis: 1) Arginine and 
proline;
2) Glycine, serine, and 
threonine;
3) Alanine, aspartate, and 
glutamate 
Plasma levels of amino acids 
can be used to assess Ps 
severity and track response to 
treatment
Izaki et al79 To determine the 
differences in platelet-
activating factor and 
arachidonic acid 
metabolites in the 
plasma of psoriasis and 
palmoplantar pustulosis 
pts compared to healthy 
controls
12 healthy controls
Pretreatment: 25 Ps adults 
and children
33 adults with 
palmoplantar putulosis
Posttreatment: 16 Ps 
patients
11 palmoplantar putulosis 
patients
Radioimmuno 
assay
Ps versus control: PAF, LTB4 
higher in Ps
No difference in TXB2 and 
PGE2
Palmoplantar pustulosis 
versus control: Similar, but 
statistically insignificant, 
increases in PAF, LTB4
PAF may contribute to the 
acute phase of inflammation 
in psoriasis by bolstering the 
inflammatory response of 
leukocytes and endothelial cells
Kang et al70 To determine differences 
in serum metabolomic 
profiles between Ps 
patients and healthy 
controls and identify 
biomarkers for Ps
14 Ps patients – 15 age- 
and gender-matched 
healthy controls
GC–MS Ps had higher asparagine, 
aspartic acid, isoleucine, 
phenylalanine, ornithine and 
proline
Ps also had higher lactic acid, 
urea
Ps had lower crotonic acid, 
azelaic acid, ethanolamine, and 
cholesterol
Glycolysis pathway and amino 
acid metabolic activity are 
increased in Ps
Metabolite changes likely 
due to increased demand 
for protein biosynthesis and 
keratinocyte hyperproliferation
Grattan 
et al77
To determine whether 
low blood levels 
of certain essential 
fatty acids and their 
metabolites are 
correlated with Ps, acne 
vulgaris, and icthyosis 
vulgaris
21 chronic plaque Ps 
(12 mild, 6 moderate, 
3 severe, 17 on topicals)
20 acne
13 icthyosis vulgaris
35 healthy volunteers
GC Arachidonic acid lower in all 
3 study groups compared to 
controls
Docosapentaenoic acid in all 
3 study groups lower than 
controls
DGLA was increased in Ps, 
normal in acne, and decreased 
in icthyosis
Although certain EFA 
abnormalities are shared by 
various skin disease, the overall 
pattern of EFA metabolism 
abnormalities seem to be 
unique for each disease state
Madsen 
et al73
To determine whether 
metabolite concentration 
variations in RA can lead 
to biomarker discovery 
which can increase 
specificity of diagnosis in 
early RA patients
25 adults with RA
20 adults with PsA
10 healthy controls
LC–MS,  
GC–MS 
Metabolic profile of RA versus 
PsA: Ps had lower glutamine, 
heptanoic acid, succinate, 
pseudouridine, inosine, 
guanosine, arabitol, cystine, 
cysteine, phosphoric acid
Pso had higher aspartic acid, 
glutamic acid, glutamate, 
histidine, serine, arachidonic 
acid, cholesterol, threonic 
acid, 1-monooleoylglycerol
Metabolic profiling can 
help diagnose patients with 
autoimmune diseases that lack 
specific criteria such as PsA 
and RA
Metabolic profiles can help 
distinguish PsA from RA
(Continued)
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a paramount role in cellular protein synthesis and growth, 
may experience higher rates of consumption by overactive 
immune cells in psoriasis patients. However, asparagine 
experiences spontaneous deamidation and breakdown in 
environments of high oxidative stress, such as the psoriatic 
inflammatory milieu.47 Therefore, lower levels of aspara-
gine in psoriasis patients may reflect the high cell turnover 
and chronic inflammatory state seen in psoriatic disease. 
Another key finding of the Armstrong study was the level 
of alpha-ketoglutaric acid, which was higher in psoriasis, 
but lower in psoriatic arthritis.47 In addition to its role as a 
citric acid cycle intermediate, alpha-ketoglutarate can be 
converted to glutamate, which may then be used to produce 
proline, a major substrate of collagen synthesis.68 Thus, 
alpha-ketoglutaric acid may be high in psoriasis as a result 
of increased energy demand secondary to hyperprolifera-
tion, but low in psoriatic arthritis due to rapid consump-
tion for collagen synthesis.69 Similarly, other serum-based 
metabolomic studies have found amino acid changes con-
sistent with the model of high cell turnover suggested by 
Armstrong. A 2015 LC–MS study conducted by Kamleh 
et al69 and a 2016 GC–MS study by Kang et al70 revealed 
increased activity in the urea cycle and the arginine and 
proline pathway. This pattern is also found in other hyperp-
roliferative states, such as wound healing.71 Together, these 
studies show that psoriasis has metabolic effects that are 
not limited to the skin, but are appreciable at a systemic 
level. Interestingly, Kamleh et al saw increased levels of 
isoleucine69 and Kang et al found elevations in isoleucine, 
leucine, and valine.70 Incidentally, these branched chain 
fatty acids are also elevated in diabetes and cardiovascular 
disease and may provide a biochemical link between pso-
riasis and its systemic cardiometabolic comorbidities.4,22,72
Serum amino acids in psoriasis patients not only pro-
vided insights into disease pathogenesis, but may also be 
useful as biomarkers for disease severity and monitoring 
of therapeutic response. For example, the Kamleh group 
correlated increases in urea cycle amino acids, such as 
ornithine, arginine, and citrulline with psoriasis severity 
as measured by psoriasis area and severity index (PASI) 
score.69 In addition, increases in proline, and hydroxy-
proline, amino acids important for collagen synthesis, 
were also correlated with disease severity and authors 
suggested that hydroxyproline may be an indicator of 
psoriatic arthritis. Furthermore, Kamleh et al69 found 
that etanercept therapy normalized the concentrations 
of ornithine, arginine, threonine, methionine, glutamine, 
glycine, citrulline, and proline in psoriasis patients to that 
of healthy controls. These results suggest that amino acid 
biomarkers may be used to guide therapy and identify 
patients at risk of psoriatic arthritis and complications 
from more severe disease.
Serum-based metabolomics has also been used to distin-
guish psoriatic disease from other autoimmune conditions. 
Using a combination of LC–MS and GC–MS, Madsen et al 
compared serum metabolites between patients with rheu-
matoid arthritis, psoriatic arthritis, and healthy controls. 
Their study identified characteristic profiles of metabolite 
changes that could be used to differentiate the serum of 
psoriatic arthritis from rheumatoid arthritis with a sensitivity 
of 90% and a specificity of 94%.73 Among other metabolite 
changes, patients with psoriatic arthritis were found to have 
higher levels of glutamic acid and serine and lower levels of 
glutamine relative to rheumatoid arthritis. This study, like 
the one reported by Kamleh et al, also found statistically dif-
ferent concentrations of metabolites in study group patients 
Studies Study objectives Subjects Techniques Results Implications
Bilgiç et al76 To investigate the 
dysregulation of 
l-arginine-NO pathway 
in Ps by assessing levels 
of homocysteine, ADMA, 
and l-arginine–NO 
pathway products
42 chronic plaque Ps
48 healthy controls
HPLC–MS Homocysteine and ADMA 
were higher in Ps compared 
to controls
PASI scores were correlated 
with the ADMA level, and 
l-arginine/ADMA ratio, but not
homocysteine, l-arginine, or 
citrulline
Homocysteine was positively 
correlated with ADMA, 
SDMA, l-NMMA, but 
negatively correlated with 
l-arginine, l-arginine/ADMA
High homocysteine and ADMA 
in Ps increase CVD risk in Ps
Increased ADMA may also 
contribute to Ps pathogenesis 
by inhibiting l-arginine–
NO pathway and reducing 
cutaneous NO, which inhibits 
keratinocyte proliferation
Abbreviations: ADMA, asymmetrical dimethyl arginine; CVD, cardiovascular disease; DGLA, dihomo-γ-linolenic acid; EFA, essential fatty acids; GC, gas chromatography; 
HPLC, high performance liquid chromatography; HRMS, high-resolution mass spectrometry; LC, liquid chromatography; LTB4, leukotriene B4; MS, mass spectroscopy; 
NMMA, NG-monomethyl arginine; PASI, psoriasis area and severity index; PGE2, prostaglandin E2; Ps, psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SDMA, 
symmetric dimethylarginine; TNF, tumor necrosis factor; TXB2, thromboxane B2.
Table 4 (Continued)
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versus control patients,69 further underscoring the potential 
of metabolomic biomarkers in detecting and classifying 
disease. Studying the metabolic profiles of these patients 
and standardizing concentration criteria could lead to novel 
diagnostic techniques with improved specificity in clinically 
equivocal cases.
Understanding metabolic perturbations in psoriasis can 
also inform disease prognosis and comorbidities. In recent 
years, cardiovascular disease has been identified as a significant 
comorbidity in the psoriatic population, perhaps related to high 
levels of inflammation.74,75 The amino acid, homocysteine, 
has been independently associated with an increased risk of 
cardiovascular events, which is thought to be mediated by the 
accumulation of asymmetrical dimethyl arginine (ADMA), a 
NOS inhibitor that causes endothelial dysfunction.76 A 2015 
study by Bilgiç et al measured plasma homocysteine, ADMA, 
and other NOS pathway metabolites in psoriasis patients to 
further define the relationship between hyperhomocysteinemia, 
psoriasis, and cardiovascular risk. Results from this study 
demonstrated that although both homocysteine and ADMA 
concentrations were significantly increased in psoriasis patients 
versus healthy controls, the severity of psoriasis (assessed with 
PASI scoring) was only positively correlated with ADMA and 
the ratio of ADMA to l-arginine, but not homocysteine.76 
Thus, while ADMA’s inhibitory effects on cutaneous NOS 
may reduce epidermal NO, thereby promoting keratinocyte 
hyperproliferation in psoriasis, its inhibition of endothelial 
NOS may contribute to the increased cardiovascular risk in 
psoriasis patients.76 Consequently, serum ADMA has the 
potential to be a useful predictor of subclinical cardiovascular 
disease in psoriasis patients.
In addition to lipids and amino acids, arachidonic acid 
metabolites have also been investigated in the serum of 
psoriasis patients. In contrast to skin metabolomics studies, 
several blood-based studies have found that arachidonic acid 
levels were lower in psoriasis.47,69,77 However, another study 
found LTB4 and platelet activating factor, a chemotactic 
agent and stimulator of the arachidonic acid pathway,78 
were present at higher concentrations in psoriasis patients.79 
 Platelet activating factor is thought to bolster the inflam-
matory response of leukocytes and endothelial cells in both 
psoriasis and palmoplantar pustulosis.79
Overall, blood-based metabolomics offers a global picture 
of how psoriatic disease affects the body’s metabolic path-
ways. Although it may be difficult to determine if circulating 
biochemical shifts are the cause or effect of psoriatic disease, 
blood metabolomics can be used to understand the systemic 
changes in psoriasis that lead to metabolic comorbidities. 
This avenue of research is particularly interesting because 
psoriasis patients had elevated levels of phenalanine45,69,70 
and isoleucine,69,70 which have been implicated in obesity, 
diabetes, and cardiovascular disease.4,22,72 Increased levels of 
these metabolites could potentially serve as a marker of future 
cardiometabolic disease and guide the management of pso-
riatic comorbidities. The blood is also an excellent medium 
for detecting exogenous metabolites from the gut or skin 
microbiome that may influence host inflammatory pathways. 
Blood-based metabolome studies in cardiovascular and dia-
betes research have already revealed bacterial metabolites that 
are transferred to the host and promote insulin resistance24 
and atherosclerotic plaque formation.6,23 Thus, the profile 
of bacterial metabolites may be a more reliable indicator of 
disease risk than shifts in particular microbial species. In 
addition to the microbiome, the effects of other exogenous 
factors, such as diet and stress, can also be assessed through 
blood metabolomics. A better understanding of the mecha-
nistic links between the microbiome, diet, psoriasis, and 
its metabolic comorbidities can lead to new strategies for 
cardiometabolic screening and disease management.
Urine
The utility of a urine-based approach to metabolomic analy-
ses can be appreciated for its easy, noninvasive collection 
method, and its richness in body metabolites and other non-
cellular products. Currently in the biomedical literature, only 
a small number of metabolomics studies analyze urine from 
psoriasis and/or psoriatic arthritis patients using proton NMR 
(1H NMR) or LC–MS attempting to identify distinct biomark-
ers that indicate psoriatic disease activity and/or severity and 
distinct biomarkers to predict and monitor response to the 
treatment (Table 5).
In 2015, a study by Setkowicz et al identified baseline 
biomarkers in patients with psoriasis and psoriatic arthritis by 
analyzing the urinary metabolites of 12(S)-HETE in relation 
to the severity of their skin lesions. LC–MS showed signifi-
cantly higher tetranor-12(S)-HETE metabolite excretion in 
urine of patients with psoriasis whereas 12(S)-HETE was 
decreased relative to controls.80 The study proposed that an 
altered, accelerated metabolism of 12(S)-HETE in psoriasis 
patients explained the increase in the urinary metabolite 
product.80 12(S)-HETE is an arachidonate LOX product that 
acts as a potent leukocyte chemoattractant, which has been 
shown to be found in increased amounts in lesional skin in 
psoriasis. The accelerated metabolism theory at least partly 
supports the levels of 12(S)-HETE and tetranor-12(S)-HETE 
found in psoriasis patients. This metabolic profile and levels, 
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however, did not correlate with disease activity or severity. 
The study concluded that the accelerated conversion of 
12(S)-HETE to tetranor-12(S)-HETE may be secondary to 
skin inflammation-induced microsomal beta-oxidation and 
may be useful as a marker for psoriasis.80
Other potential urinary biomarkers were investigated by 
Alonso et al who compared the metabolite profiles of psoria-
sis, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease, 
ulcerative colitis, and systemic lupus erythematous. Psoriasis 
and psoriatic arthritis were found to have lower levels of 
citrate, alanine, methylsuccinate, trigonelline, carnitine, and 
hippurate relative to controls.81 In psoriatic arthritis patients, 
citrate levels were inversely correlated with disease activity81 
and may useful for monitoring of therapeutic response and 
disease severity. Subsequent clustering analysis demonstrated 
that the urine metabolite profiles could be divided into three 
main groups. Psoriasis and psoriatic arthritis comprised one 
group, sharing five metabolite associations, whereas the 
second group of Crohn’s disease and ulcerative colitis shared 
six metabolite associations.81 The third group, composed of 
rheumatoid arthritis and lupus samples, shared three metabo-
lite associations. Like the blood-based study conducted by 
Madsen’s group, these results suggest that psoriatic disease 
and rheumatoid arthritis have distinct metabolite profiles that 
may be used to aid in differential diagnosis.
Urinary biomarkers may also help predict or monitor 
treatment response. A 2013 study by Kapoor et al analyzed 
changes in urinary metabolic profiles before and during 
therapy with anti-tumor necrosis factor-alpha (anti-TNFa) 
medications infliximab or etanercept in 20 psoriatic arthritis 
patients and 16 rheumatoid arthritis patients by 1H NMR. 
Both psoriatic arthritis and rheumatoid arthritis patients had 
higher levels of glutamine, phenylacetic acid, and histamine 
in baseline urine samples and higher levels of methylamine 
and creatinine in the 12-week urine samples during treat-
ment.82 Elevated levels of these amino acids and their 
byproducts can be explained by increase in cell turnover and 
accelerated muscle breakdown due to chronic TNFa stimu-
lation causing a cachexia-like effect.82 Urinary metabolite 
profiles may, therefore, be used to predict and monitor treat-
ment response. Differences in metabolic changes between 
rheumatoid arthritis and psoriatic arthritis with anti-TNFa 
were not investigated due to small patient numbers. However, 
it was found that infliximab and etanercept alter metabolites 
in the urine differently. With infliximab treatment, there were 
high urinary metabolite levels of hippuric acid, citrate, and 
lactic acid; whereas with etanercept treatment, there were 
high urinary metabolite levels of choline, phenylacetic acid, 
urea, creatine, and methylamine.82 Although infliximab and 
etanercept were previously thought to act primarily on TNFa, 
the unexpected difference in urinary metabolite profiles may 
reflect differences in unknown additional mechanisms of 
action.82 Although etanercept and infliximab share immu-
nomodulating effects, they were found to induce different 
patterns of gene suppression. Infliximab downregulated 
many Th1 genes, whereas etanercept suppressed genes pro-
moting follicular dendritic cell development and lymphoid 
neo-organogenesis.83
The overall conclusions of these studies highlight the 
possible role of urine metabolomics as a convenient, non-
invasive method of identifying biomarker profiles, predicting 
therapeutic response, and monitoring long-term treatment 
outcomes. Urine metabolomics is thus, exceptionally well 
suited for application to personalized medicine. In the 
future, the urine metabolome may be used to biochemically 
characterize and distinguish between psoriatic subtypes and 
tailor treatment to individual metabolic phenotypes. However, 
investigations on urinary metabolomics analyses in psoriasis 
and psoriatic arthritis patients are scarce and current data on 
discriminating urinary biomarkers for psoriasis and psoriatic 
arthritis are not specific. Further research is warranted involv-
ing a greater number of cohorts to identify characteristic 
urinary metabolic profiles in psoriasis and psoriatic arthritis.
Conclusion
Metabolomics has the potential to greatly transform our 
understanding of psoriatic disease. Already, investigations 
of the metabolome in skin, blood, and urine samples have 
revealed interesting trends in metabolite differences between 
healthy individuals and those with psoriasis. Targeted analy-
ses of the arachidonic acid pathway demonstrate increases in 
leukotriene branch intermediates in psoriatic skin,62,63,65 and 
urine,80 although findings in blood samples were mixed.69,77,79 
These results suggest that leukotrienes may play an impor-
tant role in the local inflammatory milieu, but may not be a 
significant driver of systemic inflammation.
While targeted analyses have enhanced our understand-
ing of known inflammatory pathways intermediates in 
psoriasis, untargeted metabolomics studies have uncovered 
new metabolites linked to psoriatic disease. For example, 
untargeted studies in both blood and skin samples have 
reported increased levels of taurine,46,49,69 glutamic acid,45,46,69 
and phenylalanine.45,69,70 These perturbations in endogenous 
metabolites have not previously been described in association 
with psoriasis and represent some of the unique contributions 
untargeted metabolomics has made to psoriasis research. 
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Table 5 Metabolomics studies of psoriasis using urine samples
Studies Study objectives Subjects Techniques Key results Implications
Alonso et al81 Identification of 
diagnostic biomarkers 
in urine metabolome of 
RA, Ps, PsA, UC, CD, 
and SLE
Discovery: 200 in each 
of 6 disease cohorts (RA, 
PsA, Ps, UC, CD, and SLE)
100 healthy controls
Validation: 200 in each of 
6 disease cohorts (RA, 
PsA, Ps, UC, CD, and SLE)
200 healthy controls
1H NMR Metabolite profiles cluster 
into 3 groups (Ps and PsA, 
CD and UC, and RA and SLE)
Ps and PsA had lower citrate, 
alanine, methylsuccinate, 
trigonelline, carnitine, 
hippurate compared to 
controls
Citrate inverse correlated 
with disease activity in PsA
Metabolite profiles can 
be used to diagnose 
and distinguish between 
autoimmune diseases, such 
as PsA and RA
Kapoor et al82 Determining changes in 
urine metabolic profiles 
in RA and PsA patients 
before and during 
therapy with anti-TNF 
to predict response 
16 RA patients
20 PsA patients before 
and during therapy with 
infliximab or etanercept
1H NMR Baseline RA, PsA
Higher glutamine, 
phenylacetic acid, histamine
After treatment in RA, PsA
Infliximab treatment 
increased hippuric acid, 
citrate, lactic acid
Etanercept increased choline, 
phenylacetic acid, urea, 
creatine, and methylamine
Higher levels of methylamine 
and creatinine at 12 weeks
Metabolomic profiles may be 
used to predict and monitor 
response to anti-TNF 
therapy in PsA and RA
Setkowicz et al80 Determine frequencies 
of the genetic variants 
ALOX12 rs1126667 
and ALOX15 
rs11568070 in cases and 
controls, and compare 
urinary metabolites of 
12(S)-HETE in Ps and 
healthy controls
200 Patients Ps stratified 
by severity
HPLC–MS-MS Ps had higher urinary 
Tetranor-12(S)-HETE, lower 
12(S)-HETE, but levels did 
not correlate severity
No difference in genotype 
and allelic distributions of 
ALOX12 rs1126667 and 
ALOX15 rs11568070 in Ps 
and controls
Systemic metabolism of 
12(S)-HETE is accelerated 
in psoriasis and this cannot 
be explained by genetic 
differences in ALOX12 
rs1126667 and ALOX15 
rs11568070 polymorphisms
Abbreviations: CD, Crohn’s disease; HETE, hydroxyeicosatetraenoic acid; 1H NMR, proton nuclear magnetic resonance; HPLC, high performance liquid chromatography; 
MS-MS, tandem mass spectrometry; Ps, psoriasis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematous; TNF, tumor necrosis factor; UC, 
ulcerative colitis.
The findings not only provide a new layer of information 
about disease processes, such as local and systemic increases 
in cell proliferation, inflammation, and cell turnover, but 
also suggest novel biomarkers that can help us characterize 
psoriatic subtypes and differentiate psoriasis and psoriatic 
arthritis from similar conditions. As Madsen et al have dem-
onstrated, panels of metabolites can potentially aid in next 
generation diagnosis with high sensitivity and specificity.73 
Furthermore, the untargeted metabolomics approach has 
revealed new avenues for therapeutic advancement. Despite 
improved efficacy over topicals and nonselective traditional 
systemics, expensive biologics have notoriously high rates of 
relapse. Currently, anti-TNFa biologics, such as etanercept, 
infliximab, and adalimumab have relapse rates of 85%,84 
72%,84 and 62%,85 respectively. Studying the metabolites 
that did not normalize with topical corticosteroids and anti-
TNF therapies49,69,82 may offer insight into the mechanisms 
for disease relapse and help identify new pathways that can 
be targeted for a sustained cure.
Although metabolomics has proved to be a valuable 
research tool in psoriasis research, it has important limita-
tions, such as cost, lack of standard diagnostic concentration 
criteria, and need for mechanistic validation. For example, 
the development of a standard set of concentration criteria 
has been hampered by technical challenges in absolute 
metabolite quantification. In LC–MS, a metabolite’s signal 
intensity depends not only on concentration but also on the 
matrix in which the sample is analyzed.33 Ion suppression 
and other matrix effects can cause inaccurate measurements 
of metabolite concentration.33 Stable isotope standards can 
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be a potential solution, but costs are often prohibitive for 
large scale metabolomics.33 While NMR has better absolute 
quantification capabilities, it is less sensitive and its use in 
untargeted metabolomics suffers from problems relating to 
peak overlap, which can compromise accurate determinations 
of peak area in NMR spectra.86 Consequently, untargeted 
metabolomics studies are, generally, only semiquantitative 
and typically report findings in terms of relative quantifica-
tion (i.e., fold change) instead of absolute concentration.31 
It is relatively easier, although still costly, to determine 
absolute metabolite quantities in targeted metabolomics. 
Recently, the development of commercial kits with standard 
mixtures of stable isotope labeled internal standards have 
allowed for a more standardized and cost-effective approach 
to metabolomics.31 As absolute quantification capabilities 
improve, diagnostic standards can be developed for clinical 
use. Another key limitation of metabolomics data are the 
potential for overinterpretation. While pathway and network 
analyses have provided crucial biologic context to metabo-
lomics data, it is important to note that these data provide 
evidence of association and not necessarily causation. Further 
mechanistic studies are needed to understand its role in the 
pathogenesis of psoriatic disease.
One powerful way to understanding the pathogenic role 
of metabolite perturbations is to combine metabolomics 
datasets from other “-omics” fields. An integrated “-omics” 
approach would allow researchers to account for influences 
from genetic, environmental, dietary, and microbial factors in 
a multilevel biologic phenotype that can be used for person-
alized medicine. Already, several different approaches have 
been developed for the integration of multiple dimensions of 
“-omics” data, such as concatenation-based integration, trans-
formation-based integration, and model-based integration.87 
For example, Bayesian networks are a concatenation-based 
integration strategy that can be used to model conditional 
dependencies between gene expression, proteins, and 
metabolites.88 Recently, Guo et al have used a combination 
of blood-based metabolomics and whole exome sequencing 
to assess the biologic significance and penetrance of genetic 
mutations in a cohort of 80 healthy volunteers who were free 
of diagnosed disease at the time of sampling.89 This study 
identified abnormalities in metabolites involved in lipolysis, 
glycolysis, and branched chain amino acid metabolism in 
subjects with genetic mutations associated with diabetes who 
were later diagnosed with the disease.89 Guo’s study provides 
an example of how metabolomics data can provide insight 
into the clinical significance of other “-omics” data especially 
in detecting preclinical disease and assessing personalized 
disease risk.89 A similar strategy can be useful for individual-
ized medical management in psoriasis, which has complex, 
multifactorial determinants of disease risk and phenotype. 
Moving forward, the next challenge of personalized medicine 
in psoriatic disease will lie in translating massive, multidi-
mensional files of individualized data to better patient care 
in the clinical setting.
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